Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors.
The company said $250 million in cash was provided at closing, with another $125 million in debt available.
Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.
The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.
Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.
Price: 4.29, Change: +0.02, Percent Change: +0.35
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。